GlassScriptPhysician profile
Melanie Mari Gregory
NPI 1639634306
$3,352.14
in general payments reported to CMS, 2019-2025
26 companies · $960 in 2025
The $960 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $112 · 2022: $285 · 2023: $917 · 2024: $1,078 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,955.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $347.80 | 2022-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Viiv Healthcare Company | $345.83 | 2023-2024 | Apretude, Cabenuva |
| Lundbeck LLC | $292.15 | 2023-2025 | Rexulti |
| Alkermes, INC. | $225.06 | 2022-2024 | Aristada, Vivitrol, Lybalvi |
| Axsome Therapeutics, INC. | $213.93 | 2023-2025 | Auvelity |
| Exact Sciences Corporation | $204.35 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $199.54 | 2023-2025 | |
| Gilead Sciences, INC. | $199.46 | 2021-2025 | |
| Lilly USA, LLC | $163.19 | 2022-2024 | Mounjaro, Zepbound |
| Braeburn INC. | $146.26 | 2024-2025 | Brixadi |
| E.R. Squibb & Sons, L.L.C. | $131.69 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $130.04 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $124.76 | 2024-2025 | Invega Sustenna |
| Indivior INC. | $109.39 | 2024-2025 | Sublocade |
| Ironshore Pharmaceuticals INC. | $91.52 | 2023-2024 | Jornay Pm |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $58.58 | 2023-2024 | Qelbree |
| Novo Nordisk INC | $54.79 | 2025 | Wegovy, Ozempic |
| Teva Pharmaceuticals USA, INC. | $42.03 | 2022-2024 | Austedo Xr |
| Hologic Sales and Service, LLC | $41.98 | 2022-2024 | Aptima, Thinprep 2000 Processor |
| Averitas Pharma INC. | $39.92 | 2025 | Qutenza |
| Neurocrine Biosciences, INC. | $38.26 | 2024 | Ingrezza |
| Phadia US INC. | $36.05 | 2022-2023 | Immunocap |
| Adlon Therapeutics L.P. | $35.10 | 2021 | |
| Vanda Pharmaceuticals INC. | $32.88 | 2025 | Hetlioz, Fanapt |
| Neurelis, INC. | $27.13 | 2025 | Valtoco |
| Collegium Pharmaceutical, INC. | $20.45 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Gregory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.